Shots:

• The companies collaborated to evaluate the safety, tolerability & preliminary efficacy of SpringWorks’ nirogacestat + AbbVie’s (ABBV-383) in a P-Ib study in patients with r/r MM. The study is expected to start in H1’22
• AbbVie will sponsor & conduct the P-Ib study & will assume all costs associated with the study other than expenses related to the manufacturing of nirogacestat & IPRs
• Additionally, both companies will also form a joint committee to manage the clinical study. Nirogacestat received ODD from the US FDA & EC for desmoid tumors & soft tissue sarcoma & also received FTD & BTD for progressive, unresectable, recurrent, or refractory desmoid tumors or deep fibromatosis

Ref: Globe Newswire | Image: abbvie